Novo Nordisk A/S
PROCOAGULANT ANTIBODIES

Last updated:

Abstract:

The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

Status:
Application
Type:

Utility

Filling date:

29 Jan 2021

Issue date:

5 Aug 2021